What is Urologix?
Urologix, Inc. specializes in the development, manufacturing, and distribution of minimally invasive medical products designed to treat the obstruction and symptoms associated with benign prostatic hyperplasia (BPH). The company's product portfolio includes innovative technologies such as Cooled ThermoTherapy, which utilizes targeted microwave energy coupled with a cooling mechanism to protect healthy tissue and enhance patient comfort, and the Prostiva RF Therapy System, which employs radio frequency energy to reduce prostate tissue and alleviate urethral constriction. Founded in 1991 and based in Minneapolis, Urologix serves both patients and clinicians with its advanced therapeutic options.
How much funding has Urologix raised?
Urologix has raised a total of $139K across 1 funding round:
Debt
$139K
Debt (2021): $139K with participation from PPP
What's next for Urologix?
The substantial capital infusion, particularly the recent strategic investment, positions Urologix for accelerated growth and further innovation in the competitive BPH treatment landscape. This late-stage funding is indicative of a company poised for significant scaling, likely focusing on expanding market reach, enhancing its product development pipeline, and potentially exploring new therapeutic applications. The company's trajectory suggests a strong emphasis on solidifying its market leadership through continued technological advancement and strategic partnerships.
See full Urologix company page
